CORE--MOUSE MAMMARY ORGAN CULTURE

描述：(申请人描述)本次修订的总体目标 更新申请仍有待发现和表征新的癌症 从天然产品中提取的化学防护剂。此核心取代了 续签申请的项目4。它将继续利用小鼠 乳腺器官培养(MMOC)法评价生物学效果 在最初的筛查中发现了潜在的化学预防药物 项目3.如本节目的主题所示，提取或分离 由项目2提供并被项目3视为有效销售线索的将是 首次评估对7，12-的化学预防活性 二甲基苯并(A)菲(DMBA)诱导的器官培养中的乳腺损伤。 如果提取物在这两个系统中的一个或两个系统中显示出显著的活性， 将进行生物测定引导的分级(项目2和3)。新开 在项目3中被认为处于活动状态的已标识代理再次 针对乳腺病变的形成进行评估。除了评估 提取物和纯化合物对DMBA诱导的肺泡的抑制作用 损害，我们还将评估潜在的植物提取物和纯化合物 可能具有抗雌激素活性(项目3)，因为它们对 雌激素依赖的雌激素依赖的DMBA诱导的乳腺导管病变。在……里面 总结，此MMOC核心将用于提供二次判别分析 系统选择新的化学预防药物进行进一步评估。

DESCRIPTION: (Applicant's Description) The overall objective of this revised renewal application remains to discover and characterize novel cancer chemopreventive agents derived from the natural products. This Core replaces Project 4 of the renewal application. It will continue to utilize murine mammary gland organ culture (MMOC) assay to evaluate biological effectiveness of potential chemopreventive agents identified in the initial screens of Project 3. As indicated by the theme of this program, extracts or fractions provided by Project 2 and considered as active leads by Project 3 will be first evaluated for chemopreventive activity against 7,12- dimethylbenz(a)anthracene (DMBA)-induced mammary lesions in organ cultures. If the extract shows significant activity in one or both of these systems, bioassay-guided fractionation will be performed (Project 2 and 3). Newly identified agents, which are considered active in Project 3 are again evaluated against mammary lesion formation. In addition to evaluating extracts and pure compounds for their activity against DMBA-induced alveolar lesions, we will also evaluate potential plant extracts and pure compounds with possible anti-estogenic activity (Project 3) for their effect on estrogen-proesterone-dependent DMBA-induced mammary ductal-lesions. In summary, this MMOC Core will serve to provide a secondary discriminatory assay system to select new chemopreventive agents for further evaluation.